Galapagos Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos or view top-rated stocks.

9 Wall Street analysts have issued 1 year price objectives for Galapagos' shares. Their GLPG stock forecasts range from $50.00 to $80.00. On average, they expect Galapagos' share price to reach $65.97 in the next year. This suggests a possible upside of 18.3% from the stock's current price.
View analysts' price targets for Galapagos or view top-rated stocks among Wall Street analysts.

Galapagos' stock was trading at $55.13 at the start of the year. Since then, GLPG shares have increased by 1.1% and is now trading at $55.76.
View the best growth stocks for 2022 here.

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Galapagos.

Galapagos NV (NASDAQ:GLPG) issued its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.68. The biotechnology company had revenue of $152.99 million for the quarter, compared to analyst estimates of $97.16 million. Galapagos had a negative trailing twelve-month return on equity of 4.77% and a negative net margin of 25.71%.
View Galapagos' earnings history.

6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Galapagos include Viatris (VTRS), Ono Pharmaceutical (OPHLF), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Elanco Animal Health (ELAN), Jazz Pharmaceuticals (JAZZ), Dr. Reddy's Laboratories (RDY), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Legend Biotech (LEGN), Grifols (GRFS), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS) and Perrigo (PRGO).
View all of GLPG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.79%), Great Point Partners LLC (0.55%), JPMorgan Chase & Co. (0.46%), Greenlight Capital Inc. (0.24%), Renaissance Technologies LLC (0.13%) and Goldman Sachs Group Inc. (0.10%).

GLPG stock was sold by a variety of institutional investors in the last quarter, including Silverarc Capital Management LLC, Monaco Asset Management SAM, UBS Group AG, Bank of America Corp DE, HAP Trading LLC, Greenlight Capital Inc., Goldman Sachs Group Inc., and Quantbot Technologies LP.

GLPG stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Great Point Partners LLC, Endurant Capital Management LP, Arrowstreet Capital Limited Partnership, Jane Street Group LLC, Renaissance Technologies LLC, Simplex Trading LLC, and Group One Trading L.P..

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLPG stock can currently be purchased for approximately $55.76.

Galapagos (NASDAQ:GLPG) has a market capitalization of $3.66 billion and generates $573.66 million in revenue each year.

Galapagos employs 1,309 workers across the globe.

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The official website for Galapagos is www.glpg.com. The biotechnology company can be reached via phone at (321) 534-2900, via email at [email protected], or via fax at 321-534-2901.